INTRODUCTION
The Spinophilin (Spn, Neurabin II, PPP1R9B) locus is located on chromosome 17 at position 17q21 which is in a cytogenetic area frequently associated with microsatellite instability and loss of heterozygosity (LOH). This region has a relatively high density of tumor suppressor genes, including known (e.g., BRCA1 and NME1), putative (e.g., JUP
and Prohibitin), and unidentified candidate tumor suppressor genes that are located distal to the BRCA1 locus. Most of the studies examining the 17q21 region have focused on BRCA1, which exhibits LOH at a variable frequency depending on the type and stage of the tumor, and as such, the 17q21 region has been extensively studied in breast carcinomas [1] [2] [3] . However, some studies have suggested the presence of an unknown tumor suppressor gene in the area that includes the Spn locus. LOH at 17q21.3
involving the BRCA1 locus has been observed in breast, ovarian, prostate, colorectal, gastric, renal, and lung carcinomas, as well as in salivary gland carcinosarcomas, an extremely aggressive neoplasm. This region contains both NME1 and Spn, which are only 1 Mb apart. Extensive LOH mapping in primary lung carcinomas 4 using 15 highly polymorphic markers revealed the highest LOH value (53% loss) with the D17S588 marker, which is located within the Spn locus. However, neighboring tumor suppressor genes, including BRCA1, were not significantly affected (6-13% LOH). Furthermore, previous classic cytogenetic studies that investigated the genetic association of breast and ovarian cancers with the 17q region have suggested the presence of a tumor suppressor gene located distal to BRCA1 [5] [6] [7] . The maximum LOD scores obtained for D17S588 were 5.44 in an Edinburgh study of 15 families 8 and 21.68 in an extensive analysis of 271 families with breast and breast/ovarian cancer [9] [10] , indicating the importance of this region in cancer pathology. Another study examining the correlation between p53 abnormalities and allelic loss of BRCA1, BRCA2, and adjacent loci in breast cancer found a strong correlation between p53 mutations and the specific loss of the Spn locus 1, 11 .
Although these studies suggest the existence of an unknown tumor suppressor in this region, no biological function for Spn has been reported that would explain the benefits that a tumor cell might gain by losing this gene. Furthermore, the correlation between p53 mutations and the specific loss of the Spn locus is not understood. The focus of this study was to determine how the loss of Spn may contribute to tumorigenesis and the role of p53 mutations in this process.
Two independent laboratories have shown that SPN interacts with protein phosphatase 1 (PP1) and F-actin [12] [13] . SPN contains a number of distinct domains that govern proteinprotein interactions, including two F-actin domains, three potential Src homology 3 domains, a receptor and a PP1-binding domain, a PDZ domain, three coiled-coil domains, and a potential leucine/isoleucine zipper motif 14 . 18 and its localization to the cytosol [19] [20] . One of the most important PP1 target proteins is Rb, the phosphorylated product of the retinoblastoma gene that is essential in cell cycle regulation 21 . The targeting of Rb by PP1 contributes to the dephosphorylation and subsequent activation of Rb, shutting down the G1/S phases of the cell cycle [21] [22] . Furthermore, the PP1a-mediated dephosphorylation of Rb contributes to the senescent phenotype induced by oncogenic Ras 23 and the constitutive inactivation of Rb by maintaining highly phosphorylated Rb contributes to cell cycle deregulation and tumorigenesis [24] [25] [26] . Therefore, SPN may contribute to tumorigenesis by regulating the functions of PP1 and/or Rb.
This study aimed to elucidate the molecular mechanisms that could mediate Spn lossinduced tumorigenesis, focusing on the SPN-PP1-Rb complex. We found that the loss of Spn correlated with a reduced level of PPP1CA, which in turn maintained an elevated level of Rb. This effect contributed to a functional increase in p53 activity through ARF. However, in the absence of p53, SPN enhanced the tumorigenic properties of the cells.
RESULTS
The absence of Spn contributes to Rb deregulation by maintaining a low PPP1CA level and PP1 phosphatase activity.
Because SPN binds to PPP1CA, thereby contributing to the regulation of PP1a activity, we first measured the effect of loss of Spn on PPP1CA expression. We generated mouse embryonic fibroblasts (MEFs) from Spn KO mice (Spn(-/-)) 18 and measured their PPP1CA level. An analysis of more than 20 pairs of wild-type (WT) and Spn (-/-) MEF clones demonstrated that Spn (-/-) cells contained 40% less PPP1CA protein ( Figure 1A and 1B). Despite the parallel isolation of the MEF clones (i.e., all Spn-null clones were compared to their WT sibling clones at the same growth stage and passage), their PPP1CA levels seemed to be heterogeneous, perhaps due to variations in other PPP1CA-binding proteins. To determine whether the loss of Spn also affected the PPP1CA level under stress conditions, we expressed oncogenic Ras in the cells; this has previously been reported to increase the PPP1CA level 23, 27 . The expression of oncogenic Ras induced a 50% increase in the PPP1CA level in the WT MEFs, but not in the Spn (-/-) MEFs ( Figure 1C and 1D ). We also observed that the expression of oncogenic Ras resulted in a similar increase in the SPN protein level in the WT MEFs ( Figure 1C ), suggesting that SPN and PPP1CA may be co-regulated and may both contribute to the regulation of PP1 activity. To further confirm this hypothesis, we aimed to determine whether the loss of SPN altered PP1a activity as a result of the reduced PPP1CA level. We quantified the PP1 activity as the difference in activity measured following treatment with 2.5 nM and 2.5 µM okadaic acid 28 . We observed that PP1 phosphatase activity also decreased in the Spn-null cells in parallel with PPP1CA protein level, and this decrease was not reversed following the expression of oncogenic Ras ( Figure 1E and 1F). To explore the mechanisms underlying the reduced PPP1CA level in Spn-null cells, we performed similar experiments in the presence of the proteasome inhibitor MG132. In the absence of proteasome-mediated degradation, the PPP1CA expression level and PP1 activity did not decrease in the absence of Spn ( Figure 1G and 1H). These results suggest that SPN may regulate the stability of PPP1CA, thereby regulating the activity of PP1a.
To evaluate whether the decrease in PP1 activity has physiological significance, we Figure 1) .
These results clearly demonstrate that, in the absence of SPN, PP1 exhibits reduced phosphatase activity, resulting in an elevated level of pRb.
The absence of Spn contributes to genetic alterations during MEF immortalization.
Several alterations occur during MEF immortalization, resulting in the release from senescence. These mutations tend to eliminate the G1-phase arrest imposed by MEFs lost p16INK4a expression ( Figure 3 ). All Spn-null (-/-) MEF clones were immortalized through mutations in p53 ( Figure 3 ). All of the data regarding p53 mutations that were detected based on the stabilization of p53 were confirmed by sequencing p53 mRNA (data not shown).
The lack of Spn contributes to increased p53 activity.
The lack of SPN seemed to promote p53 mutations in MEFs during immortalization, suggesting a functional relationship between SPN and p53. In addition, it has been
shown that low levels of Rb activity activate the E2F family of transcription factors, which in turn activate p19ARF, thereby contributing to p53 upregulation [37] [38] [39] 40 . To explore this possibility, we first tested the effect of shRNA-mediated SPN silencing in cells expressing the Val135 thermosensitive p53 mutant (p53(-/-) ts cells) 23 ( Figure   4A ). Switching the cultures to 32°C resulted in growth arrest, allowing only a small number of colonies to escape the arrest and to grow slowly. Silencing of SPN enhanced the observed p53-induced growth arrest in these cells. We then determined the p53 level in Spn-null MEFs. The Spn-null MEFs exhibited a slightly elevated level of p53, resulting in an elevated level of its downstream target p21waf1 ( Figure 4B ). Following induction of DNA damage with etoposide, a topoisomerase inhibitor, the increase in the p53 and p21waf1 levels were more significant in Spn-null MEFs when compared to WT cells ( Figure 4B ).
Next, we aimed to determine the importance of the increased p53 levels induced by the loss of Spn to the tumor physiology. 3-MC is a mutagen that induces tumor formation in a p53 mutation-dependent manner 41 . The addition of 3-MC enhanced the p53 response more significantly in Spn-null MEFs than in WT MEFs ( Figure 4C ). As expected, the loss of Spn delayed the onset of tumorigenesis, increasing the survival of WT mice ( Figure 4D ). However, in mice with reduced p53 levels (i.e., heterozygous for p53), the loss of Spn did not increase the survival rate ( Figure 4E ). We could not perform these experiments in p53-null;Spn(-/-) or p53-null;Spn(+/-) mice due to their rapid death days after birth (data not shown). Taken together, our data suggest that the loss of Spn increases the activity of p53.
The increased p53 activity observed in Spn-null MEFs seemed to be dependent on PPP1CA, as PPP1CA overexpression in Spn-null MEFs abolished this increase ( Figure   5A and supplementary figure 3 ). Ectopic expression of PPP1CA induced growth arrest.
Among the resistant clones the doubling time was similar to parental cells expressing only vector (data not shown). In these clones we measured PPP1CA levels (supplementary figure 4) and we found that PPP1CA levels are only slightly increased. In these cells DNA-damage treatments induce p53 stabilization but the enhancement of the signal observed in the absence of Spn is loss ( Figure 5A ). In addition, the increased p53 activity was also dependent on p19ARF. First, Spn-null MEFs exhibited increased p19ARF activation following expression of oncogenic Ras when compared to WT MEFs ( Figure 5B ). Furthermore, Spn-null MEFs expressing a p19ARF-specific shRNA did not demonstrate enhanced p53 activation following expression of oncogenic Ras when compared to the controls ( Figure 5C and 5D), confirming that p19ARF mediates the increased p53 levels observed in Spn-null MEFs. However, we were unable to detect a physical interaction between SPN and p19ARF ( Figure 5E and data not shown).
Our overall interpretation of these results is that the loss of Spn leads to Rb inactivation and the further sequential activation of E2F, ARF, and p53. Therefore, p53 plays ratelimiting, pivotal tumor suppressor role and must be mutated when SPN is nonfunctional in order for cells to become transformed.
The absence of Spn enhances the tumorigenic properties of p53-null cells.
Next, we aimed to determine the effects of p53 deficiency on Spn-null cells. To this end, we measured their ability to potentiate the p53-null phenotype. Figure 6E ). This growth inhibitory effect is similar to the growth inhibition described for PPP1CA overexpression 23 and occurred in all tested cell lines regardless of their p53 and pRb status (Supplementary Table 1 ).
DISCUSSION
Spn has been proposed to be a tumor suppressor because of its association with the LOH detected in genomic linkage studies and because loss of Spn migth contribute to lung tumorigenesis 42 . However, it is not clear how the loss of Spn might affect cellular behavior and contribute to tumorigenesis. In this study, we demonstrate that the loss of Spn affected the behavior of Rb through its ability to regulate the PPP1CA level and PP1a activity. The loss of Spn resulted in Rb inactivation and the subsequent activation of E2F, ARF, and p53. However, in the absence of p53, the elevated pRb level enhanced the tumorigenic potential of the cells (Supplementary Figure 2) . In line with this behavior, SPN has been shown to bind to the PP1-doublecortin complex, inducing its dephosphorylation 43 and inhibiting anchorage-independent growth in glioma cells [44] [45] [46] . In contrast, doublecortin-mediated growth repression is lost in the absence of Spn.
SPN appears to function as a classic scaffolding protein with no intrinsic enzymatic activity. SPN binds both PPP1CA and PPP1CC, but only marginally binds to PPP1CB 47 . SPN selectively interacts with PPP1CC in the spinal cord, and it has been suggested that this binding is at least in part responsible for the enrichment of PPP1CC at synapses 48 . Similarly, the binding of SPN to PPP1CA results in partial coupled regulation between SPN and PP1a, as lower levels of SPN led to decreased PPP1CA levels and PP1 activity. It has been recently shown that SPN is unstructured in its unbound form and binds PP1 through a folding-upon-binding mechanism, blocking one of the three putative substrate binding sites of PP1 without altering the active site 49 .
PP1 is one of the key eukaryotic serine/threonine phosphatases involved in mitotic dephosphorylation of both Rb and specific residues of p53 50 . Our data suggest that the mild p53 activation observed in the absence of Spn is related to enhanced Rb phosphorylation and activation of E2F and p19ARF because eliminating p19ARF
blocked the enhanced p53 activation induced by oncogenic stress ( Figure 5 ). It is interesting to remark the increase in p19ARF observed in Spn null compared to WT MEFs ( Fig 5B) . This increase might be dependent on E2F1 activation by pRb phosphorylation, since ARF is a target of E2F1 transcription target 51 Our data provide a functional explanation to several cancer studies that found a strong correlation between p53 mutations and the specific loss of the Spn locus (47.1 % LOH) 1, 11, 42 . Again, SPN may be involved in tumorigenesis by functioning, in association with the loss of p53 activity, as a tumor suppressor.
SPN is a regulator of PP1a, and our data strongly argue in favor of PP1a as an important tumor suppressor. The downregulation of PPP1CA, the catalytic subunit of PP1α, has been shown to maintain the hyperphosphorylated state of Rb, allowing cell growth 23 .
PPP1CA has been mapped to chromosome 11q13 56 , and translocations involving breakpoints at 11q13 have been observed in lymphomas, chronic B cell lymphocytic leukemia, and multiple myeloma [57] [58] . Results from the analysis of human solid tumors suggest that one PPP1CA allele may be lost in a high proportion of carcinomas, such as kidney and colorectal cancer 23 .
In summary, our data demonstrate that the scaffold protein SPN is important for the correct regulation of PP1α and Rb and that its absence may contribute to tumorigenesis in the absence of p53 in vivo. Therefore, the loss of Spn may induce a proliferative response by increasing Rb phosphorylation that may also be considered an antiproliferative senescence response. However, the loss of p53 activity can, in turn, bypass this senescence, thereby enhancing the malignant phenotype. Therefore, we suggest that SPN may be a novel tumor suppressor, reinforcing the role of PP1α as a tumor suppressor.
MATERIALS AND METHODS
Cell culture, retroviral vectors and gene transfer. Cells were generated and characterized following the same experimental procedure described in [59] [60] . 3T3 protocol was conducted as previously described in 30 . Temperature shifts and cell proliferation analysis were performed as described in [61] [62] . Proliferation Assays, were performed for MTT colorimetric read-out as previously described in 63 . Cell cycle analysis was assessed using flow cytometry by propidium iodide (Sigma) staining as described in 65 . A total of 10,000 size gated cells were analyzed by
FACSCalibur (BD Biosciences).
Design of shRNA against Spn. An shRNA against Spn was designed using the 'Ambion siRNA target finder' and the 'Qiagen siRNA design tool' to choose the appropriate hairpin oligonucleotides, which were then cloned in a pRetrosuper vector.
An shRNA against PPP1CA was described in 23 . Protein phosphatase assays. PP1 activity was determined using standard procedures, as described by the vendor (Anaspec) [66] . PP activity was assayed using pNPP as a substrate, which detects both PP1 and PP2A activities. To selectively quantify PP1 activity, we used 2.5 nM okadaic acid to selectively inhibit PP2A and 2.5 µM okadaic acid to inhibit PP1. We measured PP1 activity as the difference in activity measured at 2.5 nM and 2.5 µM okadaic acid. The cell pellet was homogenized in extraction buffer (20 mM Tris-HCl, pH 7.5, 5 mM EDTA, 10 mM EGTA, 15 mM β-mercaptoethanol, 0.25 M sucrose, 0.3% Triton X-100, 5 µg/ml leupeptin, and 5 µg/ml aprotinin) and centrifuged to produce a soluble supernatant. The PP activity in the cleared supernatant was determined by measuring the absorbance at 405 nM. The incubation for determining PP activity was 10 min, and each assay contained 5 µg of protein from the cell extracts, as determined using the Bio-Rad assay (Bio-Rad, Hercules, CA).With these conditions, the PP activity was linear.
Generation
Statistical analysis. All statistics were analyzed using the SPSS statistical package (version 13.0 for Windows). A p value less than 0.05 was considered statistically significant.
Immunostaining and confocal analysis for co-localization was performed as previously indicated in 68 . The nuclei were stained with Hoechst 33258, for 3 min at room temperature prior to mounting with mowiol (Calbiochem). Images were collected by confocal laser microscopy (model TCS-SP2-AOBS, Leica, Germany).
Antibodies used were: Anti-Spinophilin: AB5669 from Chemicon; anti-p19ARF: ab80
from Abcam (104996); anti-p14ARF ab80 from Abcam (104996).
Figure Legends The data show the average measurements of ten Spn KO clones and ten WT clones. Protein was extracted at the indicated time points. Total protein was resolved using PAGE, and Rb phosphorylated at Ser807/811 (pRb) was examined using western blot.
The experiment was performed more than ten independent times, with similar results. days, the cells were serum starved, and the p53 level was examined using western blot.
The upper panel presents the p19ARF and tubulin levels, while the lower panel presents a quantification of one representative experiment out of three independent experiments.
C) The p19ARF-specific shRNA decreases p19ARF expression in Spn-null MEFs.
MEFs were transfected with pRetrosuper encoding a p19ARF-specific shRNA and selected for 7 days. After selection, the cells were serum starved, and the p19ARF protein levels were analyzed using western blot. D) The loss of ARF abolishes p53-enhanced induction following RasV12 expression. Wild-type (Spn (+/+)) or Spn-null (Spn (-/-)) MEFs expressing the p19ARF-specific shRNA or vector alone were infected with a retrovirus expressing oncogenic Ras or vector alone. After selection, the cells were serum starved, and the p53 and tubulin levels were examined. E)
Immunofluoprescence demonstrating the lack of SPN and ARF colocalization. 
